Research analysts at Morgan Stanley initiated coverage on shares of TherapeuticsMD Inc (NASDAQ:TXMD) in a note issued to investors on Friday, The Fly reports. The firm set an “equal weight” rating on the stock.

A number of other equities analysts have also recently commented on TXMD. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a report on Wednesday, May 24th. Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, June 14th. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Tuesday, July 11th. Finally, CIBC raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $16.14.

TherapeuticsMD (TXMD) opened at 6.91 on Friday. The firm’s 50-day moving average is $5.83 and its 200-day moving average is $5.56. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The firm’s market cap is $1.41 billion.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $4.25 million for the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The firm’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) earnings per share. On average, equities analysts anticipate that TherapeuticsMD will post ($0.44) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD Inc (TXMD) Coverage Initiated at Morgan Stanley” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/08/therapeuticsmd-inc-txmd-coverage-initiated-at-morgan-stanley.html.

In related news, Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares of the company’s stock, valued at $21,294.45. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its position in shares of TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares in the last quarter. Managed Account Services Inc. boosted its position in shares of TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank boosted its position in shares of TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares in the last quarter. Traynor Capital Management Inc. boosted its position in shares of TherapeuticsMD by 14.0% during the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after purchasing an additional 2,799 shares in the last quarter. Finally, Greenwood Capital Associates LLC boosted its position in shares of TherapeuticsMD by 17.5% during the 1st quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after purchasing an additional 3,022 shares in the last quarter.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.